ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves First Treatment for Adult Onset Still’s Disease
June 28, 2020The U.S. Food and Drug Administration (FDA) approved Ilaris (canakinumab) injection for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD). -
US FDA approves Novartis’s Ilaris for Active Still’s disease treatment
June 18, 2020Ilaris was previously approved for Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older. -
Novartis’ ‘life-changing’ Ilaris set for NHS funding
March 06, 2020The NHS has revealed plans to fund Novartis’ Ilaris (canakinumab), for people with rare conditions causing repeated bouts of fever, joint pains and swelling.
Pharma Sources Insight January 2025
